Keenan RJ et al. |
Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. |
1991 |
Transplantation |
pmid:1719668
|
Strasser S et al. |
The effect of FK 506 on canine pancreatic islet cell function in beagle dogs. |
1991 |
Transplant. Proc. |
pmid:1703709
|
Cryan J et al. |
FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. |
1991 |
Biochem. Biophys. Res. Commun. |
pmid:1719972
|
Ryu S and Yasunami Y |
Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. |
1991 |
Transplant. Proc. |
pmid:1703710
|
Karlsson H et al. |
The immunosuppressive agent FK506 inhibits in vitro expression of membrane-bound and soluble interleukin-2 receptors on resting but not on activated human lymphocytes. |
1991 |
Immunol. Lett. |
pmid:1720417
|
Alejandro R et al. |
Combined liver-islet allotransplantation in man under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703712
|
|
FK-506 shows similar graft survival rate to cyclosporine but fewer side effects: Pitt transplant team. |
1991 |
Nephrol News Issues |
pmid:1720511
|
Ito T et al. |
The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. |
1991 |
Transplant. Proc. |
pmid:1703716
|
Sumpio BE and Phan S |
Nephrotoxic potential of FK 506. |
1991 |
Transplant. Proc. |
pmid:1721278
|
Pichard L et al. |
Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA. |
1991 |
Transplant. Proc. |
pmid:1721279
|
Christians U et al. |
Interactions of FK 506 and cyclosporine metabolism. |
1991 |
Transplant. Proc. |
pmid:1721280
|
Wu YM et al. |
Interaction between FK 506 and cyclosporine in dogs. |
1991 |
Transplant. Proc. |
pmid:1721281
|
Andersson J et al. |
The effects of FK 506 on cytokine production are dependent on the mode of cell activation. |
1991 |
Transplant. Proc. |
pmid:1721311
|
Wang SC et al. |
FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. |
1991 |
Transplant. Proc. |
pmid:1721312
|
Woo J et al. |
Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. |
1991 |
Transplant. Proc. |
pmid:1721313
|
McCarthy SA et al. |
Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. |
1991 |
Transplant. Proc. |
pmid:1721314
|
Tzakis AG et al. |
FK 506 versus cyclosporine in pediatric liver transplantation. |
1991 |
Transplant. Proc. |
pmid:1721343
|
Mieles LA et al. |
Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. |
1991 |
Transplant. Proc. |
pmid:1721344
|
Nakazato P et al. |
Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. |
1991 |
Transplant. Proc. |
pmid:1721345
|
Nakamura K et al. |
The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. |
1991 |
Transplant. Proc. |
pmid:1721346
|
Starzl TE et al. |
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. |
1991 |
Transplant. Proc. |
pmid:1703351
|
Shapiro R et al. |
Kidney transplantation under FK 506 immunosuppression. |
1991 |
Transplant. Proc. |
pmid:1703352
|
Tzakis AG et al. |
Use of FK 506 in pediatric patients. |
1991 |
Transplant. Proc. |
pmid:1703353
|
Jain AB et al. |
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. |
1991 |
Transplant. Proc. |
pmid:1703354
|
|
Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Japanese FK 506 Study Group. |
1991 |
Transplant. Proc. |
pmid:1721374
|
Morris SM et al. |
Disruption of renal function and gene expression by FK 506 and cyclosporine. |
1991 |
Transplant. Proc. |
pmid:1721375
|
Lieberman KV et al. |
FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). |
1991 |
Transplant. Proc. |
pmid:1721376
|
Ueda D et al. |
Influence of FK 506 on renal blood flow. |
1991 |
Transplant. Proc. |
pmid:1721377
|
Pirsch JD et al. |
Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient. |
1991 |
Transplant. Proc. |
pmid:1721406
|
Shinozuka H et al. |
Effect of FK 506 on experimental liver carcinogenesis. |
1991 |
Transplant. Proc. |
pmid:1721407
|
Pelekanou V et al. |
FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. |
1991 |
Transplant. Proc. |
pmid:1721408
|
Tai J et al. |
In vivo and in vitro effect of FK 506 on rat Leydig cell function. |
1991 |
Transplant. Proc. |
pmid:1721409
|
Steinmann B et al. |
Mechanism of action of FK 506 and cyclosporin. |
1991 |
Lancet |
pmid:1704088
|
Sewing KF and Christians U |
FK 506. |
1991 |
Lancet |
pmid:1704090
|
DeValeria PA et al. |
FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model. |
1991 |
Transplant. Proc. |
pmid:1721438
|
Jiang H et al. |
Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. |
1991 |
Transplant. Proc. |
pmid:1721439
|
Sato K et al. |
Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. |
1991 |
Transplant. Proc. |
pmid:1721440
|
Katayama Y et al. |
Immunosuppressive effects of FK 506 in rat lung transplantation. |
1991 |
Transplant. Proc. |
pmid:1721441
|
Metcalfe S and Milner J |
Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. |
1991 |
Transplantation |
pmid:1710844
|
Chang JY et al. |
FK506 and rapamycin: novel pharmacological probes of the immune response. |
1991 |
Trends Pharmacol. Sci. |
pmid:1710854
|
Neuberger J |
FK 506--a promise of good things to come? |
1991 |
Hepatology |
pmid:1711005
|
Halloran PF and Madrenas J |
The mechanism of action of cyclosporine: a perspective for the 90's. |
1991 |
Clin. Biochem. |
pmid:1711939
|
Nicoletti F et al. |
FK-506 prevents diabetes in diabetes-prone BB/Wor rats. |
1991 |
Int. J. Immunopharmacol. |
pmid:1722192
|
Starzl TE et al. |
[Clinical experience with FK 506]. |
1991 |
Presse Med |
pmid:1722311
|
Granelli-Piperno A and McHugh P |
Characterization of a protein that regulates the DNA-binding activity of NF-AT, the nuclear factor of activated T cells. |
1991 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:1722332
|
Nelson PA et al. |
cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequence. |
1991 |
Gene |
pmid:1722474
|
Turka LA and Thompson CB |
Structure-function relationship of immunosuppressive drugs: a cautionary tale. |
1991 |
Hepatology |
pmid:1714876
|
Brizuela L et al. |
Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. |
1991 |
Mol. Cell. Biol. |
pmid:1715022
|
Heitman J et al. |
Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. |
1991 |
Science |
pmid:1715094
|
Morris RE |
Rapamycin: FK506's fraternal twin or distant cousin? |
1991 |
Immunol. Today |
pmid:1715165
|